20 
Dr. Campbell explained that this provision would permit a review of how 
well IBCs are performing this function. Dr. Gottesman noted NIAID is 
planning to evaluate IBC function. She questioned whether a special 
effort was required in large-scale applications. Dr. Campbell said that 
the preposed subcommittee would have the expertise to evaluate this 
aspect of IBC function. By a vote of thirteen in favor, three opposed, 
and two abstentions, the RAC accepted the Campbell amendment. 
The RAC then voted fifteen in favor, two opposed, and two abstentions to 
adopt the following amended proposal: 
"A large-scale review subcommittee of the RAC shall be established 
with responsibility for ad vising the RAC on procedures and facilities 
design pertaining to large-scale operations, and on the performance 
of local IBCs in reviewing physical containment facilities. The 
subcanmittee shall invite participation from NIH's biosafety staff 
plus OSHA, NIOSH, CDC, FDA, EPA and USEA." 
XVII. PROPOSED CONTAINMENT FOR CLONING AMONG MEMBERS OF THE ACTINQMYCETES GROUP 
Dr. Brill introduced the request (tabs 925, 926, 931/14) from Dr. Dean 
Taylor, Smith, Kline and French Laboratories. Dr. Taylor proposed 
that the third entry in Appendix E of the Guidelines be modified to 
read: 
"P2 physical containment shall be used for ENA recombinants produced 
between members of the Actinomycetes group except for those species 
which are known to be pathogenic for man, animals or plants." 
Ihis proposal was made previously by the RAC Working Group on Prokaryotic 
Host-Vectors other than E^ coli and appeared in the Federal Register , 
April 13, 1979, 44 (73): 22316. The RAC considered the proposal at its 
May 21-23, 1979 meeting and recommended to restrict this so that it did 
not include the entire Actinomycetes group but rather only the genera 
Streptomyces and Micromonospora . Tfie Director, NIH, accepted this recom- 
mendation and the action was published in the Federal Register , July 20, 
1979, 44 (141): 42916, and appears as the third entry in Appendix E of 
the Guidelines. 
Dr. Brill noted that currently the Guidelines permit P2 containment to be 
used for ENA recombinants produced between Streptomyces and Micromonospora 
Experiments using other genera of the Actinomycetes may be performed under 
P3 containment. He said there are few pathogenic organisms in the Actino- 
mycetes genera and most of those organisms are pathogenic only in compro- 
mised hosts. He moved approval of the proposal. Dr. Scandal ios concurred 
Dr. Taylor said pathogenic Actinomycetes are marginal pathogens; the hosts 
are generally compromised. 
[179] 
